

DUSA PHARMACEUTICALS INC

Form S-8 POS

August 17, 2009

**Table of Contents**

As filed with the Securities and Exchange Commission on August 17, 2009

Registration No. 333-155431

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549  
POST-EFFECTIVE AMENDMENT NO. 1 TO  
FORM S-8  
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933  
DUSA PHARMACEUTICALS, INC.  
(Exact Name of Registrant as Specified in Its Charter)**

**New Jersey**  
(State or Other Jurisdiction  
of Incorporation or Organization)

**22-3103129**  
(I.R.S. Employer  
Identification No.)

**25 Upton Drive  
Wilmington, Massachusetts 01887**  
(Address of Principal Executive Offices) (Zip Code)  
**DUSA Pharmaceuticals, Inc. 2006 Equity Compensation Plan  
DUSA Pharmaceuticals, Inc. Non-Qualified Deferred Compensation Plan  
1991 Incentive Stock Option Plan Of Deprenyl USA, Inc.  
DUSA Pharmaceuticals, Inc. 1994 Restricted Stock Option Plan  
DUSA Pharmaceuticals, Inc. 1996 Omnibus Plan, As Amended  
Stock Option Agreement For Richard C. Lufkin  
Stock Option Agreements For Scott Lundahl**

(Full Title of the Plan)

**Nanette W. Mantell, Esq.  
Reed Smith LLP**

**Princeton Forrestal Village  
136 Main Street Suite 250  
Princeton, New Jersey 08543-7839  
(609) 514-8541**

(Name and Address and Telephone of Agent for Service)

**Copies to:**

**Robert F. Doman, President and Chief Executive Officer  
DUSA Pharmaceuticals, Inc.  
25 Upton Drive  
Wilmington, Massachusetts 01887  
(978) 657-7500**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one)

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company   
(do not check if smaller reporting company)



**Table of Contents**

**INTRODUCTORY STATEMENT**

This Post-Effective Amendment to Registration Statements on Form S-8 constitutes Post-Effective Amendment No. 1 to Registration Statement on Form S-8, Registration No. 333-155431, filed November 18, 2008. This Post-Effective Amendment is being filed solely for the purpose of updating the reoffer prospectus that forms a part of this Post-Effective Amendment relating to the resale of control securities to be acquired by selling shareholders listed under the Selling Securityholders section of the prospectus. The selling shareholders have acquired or will acquire the securities pursuant to DUSA's various equity compensation plans. The reoffer prospectus contained herein has been prepared in accordance with the requirements of Part I of Form S-3 and, pursuant to General Instruction C of Form S-8, may be used for reoffers or resales of the shares that have been or will be acquired by the selling security holders.

The inclusion of the individuals listed under the Selling Securityholders section of the prospectus does not constitute a commitment to sell any or all of the stated number of shares of common stock. The number of shares offered shall be determined from time to time by each selling securityholder at their sole discretion and such individuals are listed as selling securityholders solely to register the shares that each has received or will receive under DUSA's various equity compensation plans.

**Table of Contents**

**PROSPECTUS**  
**1,313,250 Shares of Common Stock by Selling Securityholders**  
**DUSA Pharmaceuticals, Inc.**

The shares of common stock of DUSA Pharmaceuticals, Inc. covered by this prospectus may be offered and sold to the public by certain selling securityholders of DUSA. The selling securityholders have acquired or will acquire the shares under DUSA's 1991 Incentive Stock Option Plan of Deprenyl USA, Inc. (Deprenyl USA, Inc. is the former name of DUSA Pharmaceuticals, Inc.), 1994 Restricted Stock Option Plan, 1996 Omnibus Plan, as amended, 2006 Equity Compensation Plan, as amended, together with stock option agreements with Richard C. Lufkin and Scott Lundahl, individually.

Our common stock is quoted on the Nasdaq Global Market under the symbol DUSA. On August 14, 2009, the closing price of a share of our common stock on the Nasdaq Global Market was \$1.24 per share.

**Investing in our common stock involves risks. See Risk Factors beginning on page 3.**

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.**

The date of this prospectus is August 17, 2009.

---

**TABLE OF CONTENTS**

	Page
<u>DUSA Pharmaceuticals, Inc.</u>	1
<u>Risk Factors</u>	3
<u>Special Note Regarding Forward-Looking Statements</u>	16
<u>Use of Proceeds</u>	17
<u>Selling Securityholders</u>	18
<u>Plan of Distribution</u>	21
<u>Legal Matters</u>	21
<u>Experts</u>	21
<u>Where You Can Find More Information</u>	21
<u>Incorporation of Certain Documents by Reference</u>	22
<u>EX-5.1</u>	
<u>EX-23.1</u>	

You should rely only on the information contained in this prospectus or any supplement, including the documents that we incorporate by reference. We have not authorized anyone to provide you with information different from that which is contained in or incorporated by reference to this prospectus. We are offering to sell shares of common stock and seeking offers to buy shares of common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of the prospectus, regardless of the time of delivery of this prospectus or of any sale of the common stock.

---

**Table of Contents**

**DUSA PHARMACEUTICALS, INC.**

We are a vertically integrated dermatology company that is developing and marketing Levulan<sup>®</sup> photodynamic therapy, or PDT, and other products for common skin conditions. Our marketed products include, among others, Levulan<sup>®</sup> Kerastick<sup>®</sup> 20% Topical Solution with PDT, the BLU-U<sup>®</sup> brand light source, and ClindaReach<sup>®</sup>, which we acquired.

Historically, we devoted most of our resources to advancing the development and marketing of our Levulan<sup>®</sup> PDT/PD technology platform. In addition to our marketed products, our drug, Levulan<sup>®</sup> brand of aminolevulinic acid HCl, or ALA, in combination with light, has been studied in a broad range of medical conditions. When Levulan<sup>®</sup> is used and followed with exposure to light to treat a medical condition, it is known as Levulan<sup>®</sup> PDT. When Levulan<sup>®</sup> is used and followed with exposure to light to detect medical conditions, it is known as Levulan<sup>®</sup> photodetection, or Levulan<sup>®</sup> PD. The Kerastick<sup>®</sup> is our proprietary applicator that delivers Levulan<sup>®</sup>. The BLU-U<sup>®</sup> is our patented light device.

The Levulan<sup>®</sup> Kerastick<sup>®</sup> 20% Topical Solution with PDT and the BLU-U<sup>®</sup> were launched in the United States, or U.S., in September 2000 for the treatment of non-hyperkeratotic actinic keratoses, or AKs, of the face or scalp under a former dermatology collaboration. AKs are precancerous skin lesions caused by chronic sun exposure that can develop over time into a form of skin cancer called squamous cell carcinoma. In addition, in September 2003 we received clearance from the United States Food and Drug Administration, or FDA, to market the BLU-U<sup>®</sup> without Levulan<sup>®</sup> PDT for the treatment of moderate inflammatory acne vulgaris and general dermatological conditions.

Sirius Laboratories, Inc., a dermatology specialty pharmaceuticals company, was founded in 2000 with a primary focus on the treatment of acne vulgaris and acne rosacea. Nicomide<sup>®</sup>, its key product, is a vitamin-mineral product formerly prescribed by dermatologists. In March 2006, DUSA acquired Sirius Laboratories, Inc. In April 2008, we were notified by Actavis Totowa, LLC, the manufacturer of Nicomide<sup>®</sup>, that Actavis Totowa would cease manufacturing several prescription vitamins, including Nicomide<sup>®</sup>, due to continuing discussions with the FDA. As we previously disclosed, Actavis Totowa had received notice that the FDA considers prescription dietary supplements to be unapproved new drugs. In response to this notification and subsequent discussions with the FDA, we stopped the sale and distribution of Nicomide<sup>®</sup> as a prescription product in June 2008.

On August 12, 2008, we entered into a worldwide non-exclusive patent License Agreement to our patent covering Nicomide<sup>®</sup>, or License Agreement, with River s Edge Pharmaceuticals, LLC, or River s Edge, and an amendment to our Settlement Agreement with River s Edge. The amendment to the Settlement Agreement had allowed River s Edge to manufacture and market a prescription product that could be substitutable for Nicomide<sup>®</sup> pursuant to the terms of the License Agreement and changed certain payment obligations of River s Edge for sales of its substitutable product. In consideration for granting the license, we were paid a share of the net revenues, as defined in the License Agreement, of River s Edge s licensed product sales. In April 2009, we and River s Edge entered into an Amendment to the License Agreement, or License Amendment. The License Amendment grants River s Edge an exclusive license to U.S. Patent, No. 6,979,468, and a license to use all know-how and the trademark associated with the Licensed Products worldwide. Under the License Amendment, we are required to transfer all of our rights, title and interest in and to DUSA s patent, know-how and trademark relating to the Licensed Products (but not the copyright registration relating to product labeling) to River s Edge upon our receipt of \$5,000,000. Of the \$5,000,000, River s Edge is required to make a minimum guaranteed payment to us of \$2,600,000, in thirteen monthly installments of \$200,000, subject to reduction under certain conditions, and pay additional consideration of \$2,400,000 payable over time based on a share of River s Edge s net revenues as defined in the License Amendment. The License Agreement, as amended, has a term of 30 months, subject to a further extension under certain circumstances to 48 months, and may be terminated early by River s Edge on 30 days prior written notice. Under the License Agreement, River s Edge has assumed all regulatory responsibilities for the Licensed Products. If the License

**Table of Contents**

Agreement is terminated prior to the payment of the \$5,000,000, all of the rights and licenses granted by us to River s Edge will revert to us. We are recording the revenue under the License Amendment on a cash basis. We received the first \$200,000 installment payment under the License Amendment during the three-month period ended June 30, 2009. The Company has not received the payments which were due on June 1, July 1 and August 1, 2009. We are evaluating our options to collect the outstanding amounts due from River s Edge under the License Agreement, as amended, and have not yet determined our course of action.

We are marketing Levulan<sup>®</sup> PDT under an exclusive worldwide license of patents and technology from PARTEQ Research and Development Innovations, the licensing arm of Queen s University, Kingston, Ontario, Canada. In January, 2009, we filed a request for reexamination with the U.S. Patent and Trademark Office of one of the Queen s University s patents that cover our approved indication for AK. We also own or license certain other patents relating to our BLU-U<sup>®</sup> device and methods for using pharmaceutical formulations which contain our drug and related processes and improvements. In the United States, DUSA<sup>®</sup>, DUSA Pharmaceuticals, Inc.<sup>®</sup>, Levulan<sup>®</sup>, Kerastick<sup>®</sup>, BLU-U<sup>®</sup>, Nicomide<sup>®</sup>, Nicomide-T<sup>®</sup>, ClindaReach<sup>®</sup>, Meted<sup>®</sup>, and Psoriacap<sup>®</sup> are registered trademarks. Several of these trademarks are also registered in Europe, Australia, Canada, and in other parts of the world. Numerous other trademark applications are pending.

As of June 30, 2009, we had an accumulated deficit of approximately \$144,311,000. We cannot predict whether any of our products will achieve significant enough market acceptance or generate sufficient revenues to enable us to become profitable on a sustainable basis. We recorded significant impairment changes of goodwill during the fourth quarter of 2007 and the third quarter of 2008.

As of June 30, 2009, we had a staff of 85 employees, including 2 part-time employees who worked across all operating functions at DUSA.

Unless the context otherwise requires, the terms we, our, us, the Company and DUSA refer to DUSA Pharmaceuticals, Inc., a New Jersey corporation.

We were incorporated on February 21, 1991, under the laws of the State of New Jersey. Our principal executive offices are located at 25 Upton Drive, Wilmington, Massachusetts 01887 (telephone: (978) 657-7500).



**Table of Contents**

**RISK FACTORS**

Investing in our common stock is very speculative and involves a high degree of risk. You should carefully consider and evaluate all of the information in, or incorporated by reference in, this prospectus. The following are among the risks we face related to our business, assets and operations. They are not the only ones we face. Any of these risks could materially and adversely affect our business, results of operations and financial condition, which in turn could materially and adversely affect the trading price of our common stock and you might lose all or part of your investment.

This section contains forward-looking statements of our plans, objectives, expectations and intentions. We use words such as anticipate, believe, expect, future, and intend and similar expressions to identify forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risk factors described below. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this prospectus.

**Risks Related To DUSA**

***We Are Not Currently Profitable And May Not Be Profitable In The Future Unless We Can Successfully Market And Sell Significantly Higher Quantities Of Our Products.***

*If We Do Not Become Profitable, We May Need More Capital.*

We have approximately \$16,382,000 in cash, cash equivalents and marketable securities as of June 30, 2009. Our cash, cash equivalents and marketable securities should be sufficient for current operations for at least the next 12 months. If we are unable to become profitable in the near term, we may have to reduce our headcount, curtail certain variable expenses, or raise funds through financing transactions. We cannot predict whether financing will be available at all or on reasonable terms.

*If A Competitive Product Is Successful Our Market Share Could Decrease and Our Ability Become Profitable Could Be Delayed*

On May 30, 2006, we entered into a patent license agreement with PhotoCure ASA whereby we granted a non-exclusive license to PhotoCure under the patents we license from PARTEQ, for esters of ALA. Furthermore, we granted a non-exclusive license to PhotoCure for its existing formulations of its Hexvix<sup>®</sup> and Metvix<sup>®</sup> (known in the United States as Metvixia<sup>®</sup>) products for any DUSA patents that may issue or be licensed by us in the future. PhotoCure received FDA approval to market Metvixia<sup>®</sup> for treatment of AKs in July 2004 and it is directly competitive with our Levulan<sup>®</sup> Kerastick<sup>®</sup> product. Metvixia<sup>®</sup> is now commercially available and its price is comparable to the price of Levulan<sup>®</sup>. We are entitled to royalties from PhotoCure on its net sales of Metvixia, however, since it is marketed in the U.S. by a large dermatology company, which has a large sales force and considerably more resources than we have, our ability to maintain or increase our market could be significantly hampered.

*Our Ability To Become Profitable May Be Delayed Since We No Longer Sell Nicomide<sup>®</sup> As A Prescription Product.*

On August 12, 2008, we entered into a worldwide non-exclusive patent License Agreement to our patent covering Nicomide<sup>®</sup> with River's Edge Pharmaceuticals, LLC and an amendment to our Settlement Agreement with River's Edge which we entered into in October 2007 to settle certain patent litigation. The amendment to the Settlement Agreement allows River's Edge to manufacture and market a prescription product that could be substitutable for Nicomide<sup>®</sup> pursuant to the terms of the License Agreement and changes certain payment obligations of River's Edge for sales of its substitutable product. In consideration for granting the license, we were paid a share of the net revenues, as defined in the License Agreement, of River's Edge's licensed product sales under the License Agreement. In April 2009, we and River's Edge entered into an Amendment to the License Agreement (the License Amendment). The License Amendment grants River's Edge an exclusive license to U.S. Patent, No.

**Table of Contents**

6,979,468, and a license to use all know-how and the trademark associated with the Licensed Products worldwide. Under the License Amendment, we are required to transfer all of our rights, title and interest in and to our patent, know-how and trademark relating to the Licensed Products (but not the copyright registration relating to product labeling) to River s Edge upon our receipt of \$5,000,000. Of the \$5,000,000, River s Edge is required to make a minimum guaranteed payment to us of \$2,600,000, in thirteen monthly installments of \$200,000, subject to reduction under certain conditions, and pay additional consideration of \$2,400,000 payable over time based on a share of River s Edge s net revenues as defined in the License Amendment. We received the first \$200,000 installment payment under the License Amendment during the three-month period ended June 30, 2009, which is included in Product Revenues in the accompanying Consolidated Statements of Operations. We have not received payments which were due on June 1, July 1 and August 1, 2009. We are evaluating our options to collect the outstanding amounts due from River s Edge under the License Agreement, as amended, and have not yet determined our course of action. The License Agreement, as amended, has a term of 30 months, subject to a further extension under certain circumstances to 48 months, and may be terminated early by River s Edge on 30 days prior written notice to us. Under the License Agreement, River s Edge has assumed all regulatory responsibilities for the Licensed Products. If the License Agreement is terminated prior to the payment of the \$5,000,000, all of the rights and licenses granted by us to River s Edge will revert to us. Once we receive \$5,000,000 under the terms of the License Agreement, we will no longer receive any revenues from sales of this product. If the License Agreement is terminated before we receive \$5,000,000, we may consider selling the product in accordance with the Dietary Supplement Health and Education Act, but in that case, we would expect volume and revenues to be lower than historical levels.

Another company has launched a substitutable niacinamide product. In July 2009, River s Edge filed a lawsuit against it alleging infringement of this patent, and the validity of the Nicomide® patent could be tested again. It is too early in the litigation to assess the possible outcomes. Also, new products have been launched that are competing with Nicomide®.

***If Product Sales Do Not Continue to Increase, We May Not Be Able To Advance Development Of Our Other Potential Products As Quickly As We Would Like To, Which Would Delay The Approval Process And Marketing Of New Potential Products, if approved.***

If we do not generate sufficient revenues from our approved products, we may be forced to delay or abandon our development program for solid organ transplant recipients or other programs we may wish to initiate. The pharmaceutical development and commercialization process is time consuming and costly, and any delays might result in higher costs which could adversely affect our financial condition and results of operations. Without sufficient product sales, we would need alternative sources of funding. There is no guarantee that adequate funding sources could be found to continue the development of our technology.

***Any Failure To Comply With Ongoing Governmental Regulations In The United States And Elsewhere Will Limit Our Ability To Market Our Products And Become Profitable.***

The manufacture and marketing of our products are subject to continuing FDA review as well as comprehensive regulation by the FDA and by state and local regulatory authorities. These laws require, among other things:

- approval of manufacturing facilities, including adherence to good manufacturing and laboratory practices during production and storage,

- controlled research and testing of some of these products even after approval,

- control of marketing activities, including advertising and labeling, and

- state permits for the sale and distribution of products manufactured out-of-state.

**Table of Contents**

If we, or any of our contract manufacturers, fail to comply with these requirements, we may be limited in the jurisdictions in which we are permitted to sell our products. Additionally, if we or our manufacturers fail to comply with applicable regulatory approval requirements, a regulatory agency may:

send warning letters,

impose fines and other civil penalties on us,

seize our products,

suspend our regulatory approvals,

cease the manufacture of our products,

refuse to approve pending applications or supplements to approved applications filed by us,

refuse to permit exports of our products from the United States,

require us to recall products,

require us to notify physicians of labeling changes and/or product related problems,

impose restrictions on our operations, and/or

criminally prosecute us.

We and our manufacturers must continue to comply with current Good Manufacturing Practice regulations, or cGMP, and Quality System Regulation, or QSR, and equivalent foreign regulatory requirements. The cGMP requirements govern quality control and documentation policies and procedures. In complying with cGMP and foreign regulatory requirements, we and our third-party manufacturers will be obligated to expend time, money and effort in production, record keeping and quality control to assure that our products meet applicable specifications and other requirements. Manufacturing facilities are subject to ongoing periodic inspection by the FDA, including unannounced inspections. We cannot guarantee that our third-party supply sources, including our sole source supplier for the active ingredients in Levulan® and the BLU-U® or our own Kerastick® facility, will continue to meet all applicable FDA regulations. If we, or any of our manufacturers, including without limitation, the manufacturer of the BLU-U®, who has received warning letters from the FDA, fail to maintain compliance with FDA regulatory requirements, it would be time consuming and costly to remedy the problem(s) or to qualify other sources. These consequences could have a significant adverse effect on our financial condition and operations. As part of our FDA approval for the Levulan® Kerastick® for AK, we were required to conduct two Phase IV follow-up studies. We successfully completed the first study; and submitted our final report on the second study to the FDA in January 2004. The FDA has requested additional information, which was provided to them in June 2008. We are awaiting their response. Additionally, if previously unknown problems with the product, a manufacturer or its facility are discovered in the future, changes in product labeling restrictions or withdrawal of the product from the market may occur. Any such problems could affect our ability to become profitable.

***The Current Global Credit And Financial Market Conditions May Affect Our Business.***

Sales of our products are dependent, in large part, on reimbursement from government health and administration authorities, private health insurers, distribution partners and other organizations. As a result of the current global credit and financial market conditions, government authorities and private insurers may be unable to satisfy their reimbursement obligations or may delay payment. In addition, federal and state health authorities may reduce Medicare and Medicaid reimbursements, and private

**Table of Contents**

insurers may increase their scrutiny of claims. A reduction in the availability or extent of reimbursement could negatively affect our product sales and revenues.

Due to the tightening of global credit, there may be disruption or delay in the performance by our third-party contractors, suppliers or collaborators. We rely on third parties for several important aspects of our business, including the active ingredient in Levulan<sup>®</sup> and key portion of the BLU-U<sup>®</sup>, portions of our product manufacturing, royalty revenues, clinical development of future collaboration products, conduct of clinical trials and the supply of raw materials. If such third parties are unable to satisfy their commitments to us, our business would be adversely affected. See Risk Factor *Our Ability To Become Profitable May Be Delayed Since We No Longer Sell Nicom<sup>®</sup> As A Prescription Product.*

***If the Economic Slowdown Affects Our Market, Our Cash Burn Will Increase And Our Ability To Achieve Profitability Will Be Delayed.***

We are aware that a portion of our revenues is generated by patients that pay for their procedures out-of-pocket. We believe that the recession may be causing some of these patients to postpone or cancel their procedures, reducing our volume, and, if this continues, we will be required to use more of our cash. This could cause a delay in our ability to achieve profitability on a sustainable basis.

If any of our large customers were to suffer economic hardship and fail to pay us for their purchases of our products, our ability to reach profitability could be delayed.

***We Have Significant Losses And Anticipate Continued Losses.***

We have a history of operating losses. We expect to have continued losses until sales of our products increase substantially. We incurred net losses of \$6,250,000, \$14,714,000 and \$31,350,000 for the years ended December 31, 2008, 2007 and 2006, respectively, and \$2,460,000 for the six-month period ended June 30, 2009. As of June 30, 2009, our accumulated deficit was approximately \$144,000,000. We cannot predict whether any of our products will achieve significant enough market acceptance or generate sufficient revenues to enable us to become profitable on a sustainable basis, if at all.

***If We Are Unable To Obtain The Necessary Capital To Fund Our Operations, We Will Have To Delay Our Development Program And May Not Be Able To Complete Our Clinical Trials.***

We will need substantial additional funds to fully develop, manufacture, market and sell other potential products. We may obtain funds through other public or private financings, including equity financing, and/or through collaborative arrangements. Depending on the extent of available funding, we may delay, reduce in scope or eliminate our solid organ transplant recipient, or SOTR, research and development program. We may also choose to license rights to third parties to commercialize products or technologies that we would otherwise have attempted to develop and commercialize on our own which could reduce our potential revenues.

The availability of additional capital to us is uncertain. There can be no assurance that additional funding will be available to us on favorable terms, if at all. Any equity financing, if needed, would likely result in dilution to our existing shareholders, and debt financing, if available, would likely involve significant cash payment obligations and include restrictive covenants that would adversely affect the operation of our business. Failure to raise capital if needed could materially adversely affect our business, our financial condition, results of operations and cash flows.

***If We Are Not Successful With The Reexamination Of Our Patent, We Could Lose Market Share.***

In January 2009, we filed a request for reexamination with the United States Patent and Trademark Office, or USPTO, of one of the patents licensed from Queens University covering certain methods of using our product, Levulan<sup>®</sup>, for our FDA-approved indication. The USPTO accepted our request for reexamination during the first quarter of 2009. There is no guarantee that the process will be successful since the USPTO reviews the entire prosecution history of a patent during a reexamination and could

**Table of Contents**

determine that some or all of the patent claims are invalid. Typically, a reexamination takes approximately 18 months to complete. The patent is due to expire in 2013. If the USPTO finds that the patent is invalid, generic competitors could enter the market and we could lose market share. This would adversely affect our financial condition and results of operations and possibly prevent us from becoming profitable.

***We Have Limited Patent Protection, And If We Are Unable To Protect Our Proprietary Rights, Competitors Might Be Able To Develop Similar Products To Compete With Our Products And Technology.***

Our ability to compete successfully depends, in part, on our ability to defend patents that have issued, obtain new patents, protect trade secrets and operate without infringing the proprietary rights of others. We have no compound patent protection for our Levulan<sup>®</sup> brand of the compound ALA. Our basic ALA patents are for methods of detecting and treating various diseased tissues using ALA (or related compounds called precursors), in combination with light. We own or exclusively license ALA patents and patent applications related to the following:

methods of using ALA and its unique physical forms in combination with light,

compositions and apparatus for those methods, and

unique physical forms of ALA.

We also own patents covering our BLU-U<sup>®</sup> and our Kerastick<sup>®</sup>. However, other third-parties may have blue light devices or drug delivery devices that do not infringe our patents.

The patents relating to methods of using ALA for detecting or treating disease, other than for acne and our approved indication for AKs of the face or scalp, started to expire in July 2009. The patents covering our AK product do not start to expire until 2013. In January 2009, we filed an application with the USPTO for reexamination of one of our patents. If the USPTO determines that the patent is invalid, generic competitors could enter the market.

We have limited ALA patent protection outside the United States, which may make it easier for third-parties to compete there. Our basic method of treatment patents and applications have counterparts in only six foreign countries, and certain countries under the European Patent Convention. Even where we have patent protection, there is no guarantee that we will be able to enforce our patents. Additionally, enforcement of a given patent may not be practicable or an economically viable alternative.

Some of the indications for which we may develop PDT therapies may not be covered by the claims in any of our existing patents. Even with the issuance of additional patents to us, other parties are free to develop other uses of ALA, including medical uses, and to market ALA for such uses, assuming that they have obtained appropriate regulatory marketing approvals. ALA in the chemical form has been commercially supplied for decades, and is not itself subject to patent protection. There are reports of third-parties conducting clinical studies with ALA in countries outside the United States where PARTEQ, the licensor of our ALA patents, does not have patent protection. In addition, a number of third-parties are seeking patents for uses of ALA not covered by our patents. These other uses, whether patented or not, and the commercial availability of ALA, could limit the scope of our future operations because ALA products could come on the market which would not infringe our patents but would compete with our Levulan<sup>®</sup> products even though they are marketed for different uses.

On August 12, 2008, we entered into a worldwide non-exclusive patent License Agreement to our patent covering Nicomide<sup>®</sup> with River s Edge and an amendment to our Settlement Agreement with River s Edge. The amendment to the Settlement Agreement allows River s Edge to manufacture and market a prescription product that could be substitutable for Nicomide<sup>®</sup> pursuant to the terms of the License Agreement and changes certain payment obligations of River s Edge for sales of its substitutable product. In consideration for granting the license, we were paid a share of the net revenues, as defined in the

**Table of Contents**

License Agreement, of River s Edge s licensed product sales under the License Agreement. In April 2009, we and River s Edge entered into an Amendment to the License Agreement (the License Amendment ) originally entered into in August 2008. The License Amendment grants River s Edge an exclusive license to U.S. Patent, No. 6,979,468, and a license to use all know-how and the trademark associated with the Licensed Products worldwide. Under the License Amendment, DUSA is required to transfer all of its rights, title and interest in and to DUSA s patent know-how and trademark relating to the Licensed Products (but not the copyright registration relating to product labeling) to River s Edge upon our receipt of \$5,000,000. Of the \$5,000,000, River s Edge is required to make a minimum guaranteed payment to us of \$2,600,000, in thirteen monthly installments of \$200,000, subject to reduction under certain conditions, and pay additional consideration of \$2,400,000 payable over time based on a share of River s Edge s net revenues as defined in the License Amendment. We received the first \$200,000 installment payment under the License Amendment during the three-month period ended June 30, 2009, which is included in Product Revenues in the accompanying Consolidated Statements of Operations. We have not received payments which were due on June 1, July 1 and August 1, 2009. We are evaluating our options to collect the outstanding amounts due from River s Edge under the License Agreement, as amended, and have not yet determined our course of action. The License Agreement, as amended, has a term of 30 months, subject to a further extension under certain circumstances to 48 months, and may be terminated early by River s Edge on 30 days prior written notice to us. Under the License Agreement, River s Edge has assumed all regulatory responsibilities for the Licensed Products. If the License Agreement is terminated prior to the payment of the \$5,000,000, all of the rights and licenses granted by us to River s Edge will revert to us. Another company has launched a substitutable niacinamide product. In July 2009, River s Edge filed a lawsuit against them alleging infringement of this patent, and the validity of the Nicomide® patent could be tested again. It is too early in the litigation to assess the possible outcomes. Also, new products have been launched that are competing with Nicomide®. These events could negatively impact our royalty revenues and delay our ability to be profitable. Furthermore, PhotoCure received FDA approval to market Metvixia® for treatment of AKs in July 2004, and this product, which is directly competitive with our Levulan® Kerastick® product, is now commercially available. While we are entitled to royalties from PhotoCure on its net sales of Metvixia®, a large dermatology company has the marketing rights in the U.S., which may adversely affect our ability to maintain or increase our Levulan® market. While we attempt to protect our proprietary information as trade secrets through agreements with each employee, licensing partner, consultant, university, pharmaceutical company and agent, we cannot guarantee that these agreements will provide effective protection for our proprietary information. It is possible that all of the following issues could negatively impact our ability to be profitable:

these persons or entities might breach the agreements,

we might not have adequate remedies for a breach, and/or

our competitors will independently develop or otherwise discover our trade secrets.

***Litigation Is Expensive And We May Not Be Able To Afford The Costs.***

The costs of litigation or any proceeding relating to our intellectual property or contractual rights could be substantial even if resolved in our favor. Some of our competitors have far greater resources than we do and may be better able to afford the costs of complex litigation. Also, in a lawsuit against a third-party for infringement of our patents in the United States, that third-party may challenge the validity of our patent(s) as could happen in the River s Edge litigation with another company mentioned above. We cannot guarantee that a third-party will not claim, with or without merit, that our patents are not valid or that we have infringed their patent(s) or misappropriated their proprietary material. We could get drawn or decide to join into, this litigation. Defending these types of legal actions involve considerable expense and could negatively affect our financial results.

**Table of Contents**

Additionally, if a third-party were to file a United States patent application, or be issued a patent claiming technology also claimed by us in a pending United States application(s), we may be required to participate in interference proceedings in the USPTO to determine the priority of the invention. A third-party could also request the declaration of a patent interference between one of our issued United States patents and one of its patent applications. Any interference proceedings likely would require participation by us and/or PARTEQ, which could involve substantial legal fees and result in a loss or lessening of our patent protection.

***Since We Now Operate The Only FDA Approved Manufacturing Facility For The Kerastick® And Continue To Rely Heavily On Sole Suppliers For The Manufacture Of Levulan®, The BLU-U®, And Meted®, Any Supply Or Manufacturing Problems Could Negatively Impact Our Sales As Occurred With Nicomide®.***

If we experience problems producing Levulan® Kerastick® units in our facility, or if any of our contract suppliers fail to supply our requirements for products, our business, financial condition and results of operations would suffer.

Although we have received approval by the FDA to manufacture the BLU-U® and the Levulan® Kerastick® in our Wilmington, Massachusetts facility, at this time, with respect to the BLU-U®, we expect to utilize our own facility only as a back-up to our current third party manufacturer or for repairs.

Manufacturers and their subcontractors often encounter difficulties when commercial quantities of products are manufactured for the first time, or large quantities of products are manufactured, including problems involving:

- product yields,

- quality control,

- component and service availability,

- compliance with FDA regulations, and

- the need for further FDA approval if manufacturers make material changes to manufacturing processes and/or facilities.

We cannot guarantee that problems will not arise with production yields, costs or quality as we and our suppliers manufacture our products. Any manufacturing problems could delay or limit our supplies which would hinder our marketing and sales efforts. If our facility, any facility of our contract manufacturers, or any equipment in those facilities is damaged or destroyed, we may not be able to quickly or inexpensively replace it. Likewise, if there are quality or supply problems with any components or materials needed to manufacture our products, we may not be able to quickly remedy the problem(s). Any of these problems could cause our sales to suffer and could increase costs. The third-party contract relating to the supply of the active ingredient in Levulan® is scheduled to expire in December of this year. If we cannot renew this agreement on terms which are acceptable to us, we would need to find a new source of supply. If we have any delay or problems with a new manufacturer, our revenues and results of operations could suffer.

***We Have Only Limited Experience Marketing And Selling Pharmaceutical Products Outside of the United States And As A Result, Our Revenues From Product Sales May Suffer.***

If we are unable to successfully market and sell sufficient quantities of our products, revenues from product sales will be lower than anticipated and our financial condition may be adversely affected. We are responsible for marketing our products in the United States and the rest of the world, except Canada, Latin America and parts of Asia, where we have distributors. We are in negotiations with Stiefel, our distributor in Latin America, because they did not purchase the required minimum number of Kerastick®

**Table of Contents**

units under our agreement. Both parties have the right to terminate the contract. Stiefel has announced that it plans to be acquired by GlaxoSmithKline, or GSK, and we do not know whether GSK wants to continue to distribute the Levulan® Kerastick®. If our sales and marketing efforts fail, then sales of the Levulan® Kerastick®, the BLU-U®, and other products will be adversely affected, which would adversely affect our financial condition.

***The Commercial Success Of Any Product That We May Develop Will Depend Upon The Degree Of Market Acceptance Of Our Products Among Physicians, Patients, Health Care Payors, Private Health Insurers And The Medical Community.***

Our ability to commercialize any product that we may develop will be highly dependent upon the extent to which the product gains market acceptance among physicians, patients, health care payors, such as Medicare and Medicaid, private health insurers, including managed care organizations and group purchasing organizations, and the medical community. If a product does not achieve an adequate level of acceptance, we may not generate material product revenues, and we may not become profitable. The degree of market acceptance of our currently marketed products and our SOTR product candidate, if approved for commercial sale, will depend on a number of factors, including:

the effectiveness, or perceived effectiveness, of our product in comparison to competing products;

the existence of any significant side effects, as well as their severity in comparison to any competing products,

potential advantages over alternative treatments,

the ability to offer our product for sale at competitive prices,

relative convenience and ease of administration,

the strength of marketing and distribution support, and

sufficient third-party coverage or reimbursement.

***If We Cannot Improve Physician Reimbursement And/Or Convince More Private Insurance Carriers To Adequately Reimburse Physicians For Our Product, Sales May Suffer.***

Without adequate levels of reimbursement by government health care programs and private health insurers, the market for our Levulan® Kerastick® for AK therapy will be limited. While we continue to support efforts to improve reimbursement levels to physicians and are working with the major private insurance carriers to improve coverage for our therapy, if our efforts are not successful, broader adoption of our therapy and sales of our products could be negatively impacted. Although positive reimbursement changes related to AK were made over the last five years, some physicians still believe that reimbursement levels do not fully reflect the required efforts to routinely execute our therapy in their practices.

If insurance companies do not cover our products, or stop covering our products which are covered, our sales could be dramatically reduced.

***We Have Only Three Therapies That Have Received Regulatory Approval Or Clearance, And We Cannot Predict Whether We Will Ever Develop Or Commercialize Any Other Levulan® Products.***

***Our Potential Products Are In Early Stages Of Development And May Never Result In Any Commercially Successful Products.***

To be profitable, we must successfully research, develop, obtain regulatory approval for, manufacture, introduce, market and distribute our products. Except for Levulan® PDT for AKs, the BLU-U® for acne,



**Table of Contents**

the ClindaReach® pledget and several other products we acquired in our merger with Sirius, all of our other potential product candidates are at an early stage of development and subject to the risks of failure inherent in the development of new pharmaceutical products and products based on new technologies. These risks include:

delays in product development, clinical testing or manufacturing,

unplanned expenditures in product development, clinical testing or manufacturing,

failure in clinical trials or failure to receive regulatory approvals,

emergence of superior or equivalent products,

inability to market products due to third-party proprietary rights, and

failure to achieve market acceptance.

We cannot predict how long the development of our investigational stage products will take or whether they will be medically effective. We cannot be sure that a successful market will continue to develop for our Levulan® drug technology.

*We Must Receive Separate Approval For Any Drug or Medical Device Products Before We Can Sell Them Commercially In The United States Or Abroad.*

Any potential Levulan® product will require the approval of the FDA before it can be marketed in the United States. Before an application to the FDA seeking approval to market a new drug, called an NDA, can be filed, a product must undergo, among other things, extensive animal testing and human clinical trials. The process of obtaining FDA approvals can be lengthy, costly, and time-consuming. Following the acceptance of an NDA, the time required for regulatory approval can vary and is usually one to three years or more. The FDA may require additional animal studies and/or human clinical trials before granting approval. Our Levulan® PDT products are based on relatively new technology. To the best of our knowledge, the FDA has approved only three drugs for use in photodynamic therapy, including Levulan®. This factor may lengthen the approval process. We face much trial and error and we may fail at numerous stages along the way.

We cannot predict whether we will obtain any other regulatory approvals. Data obtained from preclinical testing and clinical trials can be susceptible to varying interpretations which could delay, limit or prevent regulatory approvals. Future clinical trials may not show that Levulan® PDT or photodetection, known as PD, is safe and effective for any new use we may study. In addition, delays or disapprovals may be encountered based upon additional governmental regulation resulting from future legislation or administrative action or changes in FDA policy.

We have been informed by FDA that the agency does not believe that our application for Orphan Drug designation of use of Levulan® in immunosuppressed solid organ transplant recipients should be granted. If we cannot obtain this designation, we may not continue to develop this indication. We have requested a meeting with the FDA to provide further clarification on the application and the related target population.

We have been informed by FDA that our 510(k) application for clearance of our BLU-U® to treat severe acne requires additional clinical data. After further discussions with FDA, we may decide to withdraw this application.

***Because Of The Nature Of Our Business, The Loss Of Key Members Of Our Management Team Could Delay Achievement Of Our Goals.***

We are a small company with only 85 employees, including 2 part-time employees, as of June 30, 2009. We are highly dependent on several key officer/employees with specialized scientific and technical skills

**Table of Contents**

without whom our business, financial condition and results of operations would suffer, especially in the photodynamic therapy portion of our business. The photodynamic therapy industry is still quite small and the number of experts is limited. The loss of these key employees could cause significant delays in achievement of our business and research goals since very few people with their expertise could be hired. Our growth and future success will depend, in large part, on the continued contributions of these key individuals as well as our ability to motivate and retain other qualified personnel in our specialty drug and light device areas.

***Collaborations With Outside Scientists May Be Subject To Restriction And Change.***

We work with scientific and clinical advisors and collaborators at academic and other institutions that assist us in our research and development efforts. These scientists and advisors are not our employees and may have other commitments that limit their availability to us. Although our advisors and collaborators generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. In addition, although our advisors and collaborators sign agreements not to disclose our confidential information, it is possible that valuable proprietary knowledge may become publicly known through them.

**Risks Related To Our Industry**

***Product Liability And Other Claims Against Us May Reduce Demand For Our Products Or Result In Damages.***

*We Are Subject To Risk From Potential Product Liability Lawsuits Which Could Negatively Affect Our Business.*

The development, manufacture and sale of medical products expose us to product liability claims related to the use or misuse of our products. Product liability claims can be expensive to defend and may result in significant judgments against us. A successful claim could materially harm our business, financial condition and results of operations. Additionally, we cannot guarantee that continued product liability insurance coverage will be available in the future at acceptable costs. If the cost is too high, we may have to self-insure.

***Our Business Involves Environmental Risks And We May Incur Significant Costs Complying With Environmental Laws And Regulations.***

We have used various hazardous materials, such as mercury in fluorescent tubes in our research and development activities. We are subject to federal, state and local laws and regulations which govern the use, manufacture, storage, handling and disposal of hazardous materials and specific waste products. We believe that we are in compliance in all material respects with currently applicable environmental laws and regulations. However, we cannot guarantee that we will not incur significant costs to comply with environmental laws and regulations in the future. We also cannot guarantee that current or future environmental laws or regulations will not materially adversely affect our operations, business or assets. In addition, although we believe our safety procedures for handling and disposing of these materials comply with federal, state and local laws and regulations, we cannot completely eliminate the risk of accidental contamination or injury from these materials. In the event of such an accident, we could be held liable for any resulting damages, and this liability could exceed our resources.

***We May Not Be Able To Compete Against Traditional Treatment Methods Or Keep Up With Rapid Changes In The Biotechnology And Pharmaceutical Industries That Could Make Some Or All Of Our Products Non-Competitive Or Obsolete.***

*Competing Products And Technologies Based On Traditional Treatment Methods May Make Our Products Or Potential Products Noncompetitive Or Obsolete.*

Well-known pharmaceutical, biotechnology and medical device companies are marketing well-established therapies for the treatment of AKs and acne. Doctors may prefer to use familiar methods, rather than trying our products. Reimbursement issues affect the economic competitiveness of our

**Table of Contents**

products as compared to other more traditional therapies.

Many companies are also seeking to develop new products and technologies, and receiving approval for treatment of AKs and acne. Our industry is subject to rapid, unpredictable and significant technological change. Competition is intense. Our competitors may succeed in developing products that are safer or more effective than ours. Many of our competitors have substantially greater financial, technical and marketing resources than we have. In addition, several of these companies have significantly greater experience than we do in developing products, conducting preclinical and clinical testing and obtaining regulatory approvals to market products for health care.

We cannot guarantee that new drugs or future developments in drug technologies will not have a material adverse effect on our business. Increased competition could result in:

price reductions,

lower levels of third-party reimbursements,

failure to achieve market acceptance, and

loss of market share, any of which could adversely affect our business. Further, we cannot give any assurance that developments by our competitors or future competitors will not render our technology obsolete.

On May 30, 2006, we entered into a patent license agreement with PhotoCure ASA whereby we granted a non-exclusive license to PhotoCure under the patents we license from PARTEQ, for esters of ALA. Furthermore, we granted a non-exclusive license to PhotoCure for its existing formulations of its Hexvix<sup>®</sup> and Metvix<sup>®</sup> (known in the United States as Metvixia<sup>®</sup>) products for any DUSA patents that may issue or be licensed by us in the future. PhotoCure received FDA approval to market Metvixia<sup>®</sup> for treatment of AKs in July 2004 and it is directly competitive with our Levulan<sup>®</sup> Kerastick<sup>®</sup> product. Metvixia<sup>®</sup> is now commercially available and its price is comparable to the price of Levulan<sup>®</sup>. We are entitled to royalties from PhotoCure on its net sales of Metvixia, however since it is marketed in the U.S. by a large dermatology company which has a large sales force and considerably more resources than we have, our ability to maintain or increase our market could be significantly hampered.

*Our Competitors In The Biotechnology And Pharmaceutical Industries May Have Better Products, Manufacturing Capabilities Or Marketing Expertise.*

We are aware of several companies commercializing and/or conducting research with ALA or ALA-related compounds, including: medac GmbH and photonamic GmbH & Co. KG (Germany); Biofrontera, PhotoTherapeutics, Inc. (U.K.) and PhotoCure ASA (Norway). Photocure has entered into a marketing agreement with Galderma S.A. for countries outside of Nordic countries for certain dermatology indications. We also anticipate that we will face increased competition as the scientific development of PDT and PD advances and new companies enter our markets. Several companies are developing PDT agents other than Levulan<sup>®</sup>. These include: QLT Inc. (Canada); Axcan Pharma Inc. (U.S.); Miravant, Inc. (U.S.); and Pharmacyclics, Inc. (U.S.). There are many pharmaceutical companies that compete with us in the field of dermatology, particularly in the acne and rosacea markets.

Axcan Pharma Inc. has received FDA approval for the use of its product, PHOTOFRIN<sup>®</sup>, for PDT in the treatment of high grade dysplasia associated with Barrett's Esophagus. Axcan is the first company to market a PDT therapy for this indication for which we designed our proprietary sheath device and have conducted pilot clinical trials.

We expect that our principal methods of competition with other PDT products will be based upon such factors as:

the ease of administration of our method of PDT,

**Table of Contents**

the degree of generalized skin sensitivity to light,

the number of required doses,

the selectivity of our drug for the target lesion or tissue of interest, and

the type and cost of our light systems.

Our primary competition in the acne market includes oral and topical antibiotics, other topical prescription and over-the-counter products, as well as various laser and non-laser light treatments. The market is highly competitive and other large and small companies have more experience than we do which could make it difficult for us to penetrate the market. The entry of new products from time to time would likely cause us to lose market share.

**Risks Related To Our Stock**

***Our Common Stock May Not Continue To Trade On The Nasdaq Global Market, Which Could Reduce The Value Of Your Investment And Make Your Shares More Difficult To Sell.***

In order for our common stock to trade on the Nasdaq Global Market, we must continue to meet the listing standards of that market. Among other things, those standards require that our common stock maintain a minimum closing bid price of at least \$1.00 per share. Recently, our common stock has traded at prices near and below \$1.00. On October 16, 2008, and several times since then, Nasdaq suspended the enforcement of rules requiring a minimum \$1.00 closing bid price, but the suspension ended July 31, 2009, and the rule is now in force again. If we do not continue to meet Nasdaq's applicable minimum listing standards, Nasdaq could delist us from the Nasdaq Global Market. If our common stock is delisted from the Nasdaq Global Market, we could seek to have our common stock listed on the Nasdaq Capital Market or other Nasdaq markets. However, delisting of our common stock from the Nasdaq Global Market could hinder your ability to sell, or obtain an accurate quotation for the price of, your shares of our common stock. Delisting could also adversely affect the perception among investors of DUSA and its prospects, which could lead to further declines in the market price of our common stock. Delisting would also make it more difficult and expensive for us to raise capital. In addition, delisting might subject us to a Securities and Exchange Commission rule that could adversely affect the ability of broker-dealers to sell or make a market in our common stock, thus hindering your ability to sell your shares.

***Our Results Of Operations And General Market Conditions For Specialty Pharmaceutical And Biotechnology Stocks Could Result In Sudden Changes In The Market Value Of Our Stock.***

The price of our common stock has been highly volatile. These fluctuations create a greater risk of capital losses for our shareholders as compared to less volatile stocks. From January 1, 2008 to August 10, 2009, the price of our stock has ranged from a low of \$0.87 to a high of \$2.58. Factors that contributed to the volatility of our stock during this period included:

quarterly levels of product sales;

clinical trial results;

general market conditions;

patent litigation;

increased marketing activities or press releases; and

changes in third-party payor reimbursement for our therapy.

The significant general market volatility in similar stage pharmaceutical and biotechnology companies made the market price of our common stock even more volatile.

**Table of Contents**

***Significant Fluctuations In Orders For Our Products, On A Monthly And Quarterly Basis, Are Common Based On External Factors And Sales Promotion Activities. These Fluctuations Could Increase The Volatility Of Our Stock Price.***

The price of our common stock may be affected by the amount of quarterly shipments of our products to end-users. Since our PDT products are still in relatively early stages of adoption, and sales volumes are still low, a number of factors could affect product sales levels and growth rates in any period. These could include the level of penetration of new markets outside of the United States, the timing of medical conferences, sales promotion activities, and large volume purchases by our higher usage customers. In addition, seasonal fluctuations in the number of patients seeking treatment at various times during the year could impact sales volumes. These factors could, in turn, affect the volatility of our stock price.

***If Outstanding Options, Warrants And Rights Are Converted, The Value Of The Shares Of Common Stock Outstanding Just Prior To The Conversion Will Be Diluted.***

As of August 10, 2009, there were outstanding options and warrants to purchase 4,989,000 shares of common stock, with exercise prices ranging from \$1.08 to \$31.00 per share for options, and exercise prices ranging from \$2.85 to \$6.00 per share for warrants. In addition, there are 393,250 shares of unvested common stock. The holders of the options and warrants have the opportunity to profit if the market price for the common stock exceeds the exercise price of their respective securities, without assuming the risk of ownership. The holders may exercise their securities during a time when we would likely be able to raise capital from the public on terms more favorable than those provided in these securities.

***Effecting A Change Of Control Of DUSA Would Be Difficult, Which May Discourage Offers For Shares Of Our Common Stock.***

Our certificate of incorporation authorizes the board of directors to issue up to 100,000,000 shares of stock, 40,000,000 of which are common stock. The board of directors has the authority to determine the price, rights, preferences and privileges, including voting rights, of the remaining 60,000,000 shares without any further vote or action by the shareholders. The rights of the holders of our common stock will be subject to, and may be adversely affected by, the rights of the holders of any preferred stock that may be issued in the future.

On September 27, 2002, we adopted a shareholder rights plan at a special meeting of DUSA's board of directors. The rights plan could discourage, delay or prevent a person or group from acquiring 15% or more of our common stock, thereby limiting, perhaps, the ability of our shareholders to benefit from such a transaction.

The rights plan provides for the distribution of one right as a dividend for each outstanding share of our common stock to holders of record as of October 10, 2002. Each right entitles the registered holder to purchase one one-thousandths of a share of preferred stock at an exercise price of \$37.00 per right. The rights will be exercisable subsequent to the date that a person or group either has acquired, obtained the right to acquire, or commences or discloses an intention to commence a tender offer to acquire, 15% or more of our outstanding common stock or if a person or group is declared an "Adverse Person", as such term is defined in the rights plan. The rights may be redeemed by DUSA at a redemption price of one one-hundredth of a cent per right until ten days following the date the person or group acquires, or discloses an intention to acquire, 15% or more, as the case may be, of DUSA, or until such later date as may be determined by the our board of directors.

Under the rights plan, if a person or group acquires the threshold amount of common stock, all holders of rights (other than the acquiring person or group) may, upon payment of the purchase price then in effect, purchase shares of common stock of DUSA having a value of twice the purchase price. In the event that we are involved in a merger or other similar transaction where DUSA is not the surviving corporation, all holders of rights (other than the acquiring person or group) shall be entitled, upon payment of the purchase price then in effect, to purchase common stock of the surviving corporation having a value of twice the purchase price. The rights will expire on October 10, 2012, unless previously redeemed. Our

**Table of Contents**

board of directors has also adopted certain amendments to DUSA's certificate of incorporation consistent with the terms of the rights plan.

**SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This report, including the Management's Discussion and Analysis of Financial Condition and Results of Operations, contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Securities Exchange Act of 1934 which represent our expectations or beliefs concerning future events, including, but not limited to management's statements regarding our focus for 2009, our use of estimates and assumptions in the preparation of our financial statements and policies and impact on us of the adoption of certain accounting standards, management's beliefs regarding the unique nature of Levulafin<sup>®</sup> and its use and potential use, expectations regarding the enrollment and timing of results of clinical trials and investigator studies, future development of Levulan<sup>®</sup> and our other products and other potential indications, beliefs concerning manufacture of the BLU-U<sup>®</sup>, intention to pursue licensing, marketing, co-promotion, collaboration or acquisition opportunities, status of clinical programs for all other indications and beliefs regarding potential efficacy and marketing, our beliefs regarding the safety, simplicity, reliability and cost-effectiveness of certain light sources, expectations regarding additional market expansion and increased sales, expectations regarding the marketing and distribution of Levulan<sup>®</sup> Kerastick<sup>®</sup> by Daewoong Pharmaceutical Co., Ltd. and Stiefel Laboratories, Inc., beliefs regarding the clinical benefit of Levulan<sup>®</sup> PDT for other indications, expectations regarding the confidentiality of our proprietary information, statements of our intentions to seek additional U.S. and foreign regulatory approvals, and to market and increase sales outside the U.S., beliefs regarding regulatory classifications, filings, timelines, off-label use and environmental compliance, beliefs concerning patent disputes and litigation, intentions to defend our patent estate, the impact of a third-party's regulatory compliance and fulfillment of contractual obligations, beliefs concerning the impact of price increases, expectations of increases or decreases in cost of product sales, expected use of cash resources, requirements of cash resources for our future liquidity, beliefs regarding investments, beliefs regarding economic conditions, beliefs concerning increased margins, expectations regarding outstanding options and warrants and our dividend policy, anticipation of increases or decreases in personnel, beliefs regarding the effect of reimbursement policies on revenues and acceptance of our therapies, expectations for future strategic opportunities and research and development programs and expenses, expectations for continuing operating losses and competition including from Metvixia<sup>®</sup>, expectations for growth of PDT segment revenues and reduction of Non-PDT segment revenues, expectations regarding the adequacy and availability of insurance, expectations regarding general and administrative costs, expectations regarding legal expenses, sales and marketing costs and research and development costs, levels of interest income and our capital resource needs, intention to raise additional funds to meet capital requirements and the potential dilution and impact on our business, potential for additional inspection and testing of our manufacturing facilities or additional FDA actions, beliefs regarding the adequacy of our inventory of Kerastick<sup>®</sup> and BLU-U<sup>®</sup> units, our manufacturing capabilities and the impact of inventories on revenues, beliefs regarding interest rate risks to our investments and effects of inflation, beliefs regarding the impact of any current or future legal proceedings, dependence on key personnel, and beliefs concerning product liability insurance, the enforceability of our patents, the impact of generic products, our beliefs regarding our sales and marketing efforts, competition with other companies, the adoption of our products, and the outcome of such efforts, our beliefs regarding the use of our products and technologies by third parties, our beliefs regarding our compliance with applicable laws, rules and regulations, our beliefs regarding available reimbursement for our products, our beliefs regarding the current and future clinical development and testing of our potential products and technologies and the costs thereof, the volatility of our stock price, the impact of our rights plan, the possibility that the holders of options and warrants will purchase our common stock by exercising these securities, statements regarding milestone payments to former Sirius shareholders, statements regarding the possibility of other companies distributing our products, statements regarding failure to renew the agreement with Sochinaz, statements regarding our royalty revenues, statements regarding the impact of our marketing and sales efforts on revenues and financial conditions and statements regarding the termination of the agreement with River's Edge. These forward-looking statements are further qualified by important factors that could cause actual results to



**Table of Contents**

differ materially from those in the forward-looking statements. These factors include, without limitation, changing market and regulatory conditions, actual clinical results of our trials, the impact of competitive products, pricing and timely development, FDA and foreign regulatory approval, and market acceptance of our products, environmental risks relating to our products, reliance on third-parties for the production, manufacture, sales and marketing of our products, the availability of products for acquisition and/or license on terms agreeable to us, sufficient sources of funds and profitability, the securities regulatory process, the maintenance of our patent portfolio and ability to obtain competitive levels of reimbursement by third-party payors, none of which can be assured. Results actually achieved may differ materially from expected results included in these statements as a result of these or other factors.

You should read and interpret any forward-looking statements together with the following documents:

our most recent Annual Report on Form 10-K;

our most recent Quarterly Report on Form 10-Q;

our most recent Current Reports on Form 8-K;

the risk factors contained in this prospectus under the caption **Risk Factors** ; and

our other filings with the SEC.

Any forward-looking statement speaks only as of the date on which that statement is made. We will not update any forward-looking statement to reflect events or circumstances that occur after the date on which such statement is made.

**USE OF PROCEEDS**

DUSA will not receive any proceeds from the sale of shares of common stock which may be sold pursuant to this prospectus for the respective accounts of the selling securityholders. All such proceeds, net of brokerage commissions, if any, will be received by the selling securityholders. See the sections titled **Selling Securityholders** and **Plan of Distribution**.



**Table of Contents****SELLING SECURITYHOLDERS**

This prospectus relates to shares of common stock to be offered by the selling securityholders. The table below, including the footnotes, presents information regarding the selling securityholders and the shares of our common stock that the selling securityholders may offer and sell from time to time under this prospectus. The inclusion in the table of the individuals named therein shall not be deemed to be an admission that any such individuals are affiliates of DUSA.

The following is a list, as of July 31, 2009, of the selling securityholders and the number of shares beneficially owned by each selling securityholder. The number of shares in the column **Number of Shares Owned** represents the total number of shares that a selling security holder currently owns or has the right to acquire within sixty (60) days of July 31, 2009. The number of shares in the columns **Number of Shares to be Offered** represent all of the shares that a selling securityholder may offer under this prospectus. The table and footnotes assume that the selling securityholders will sell all of such shares. However, because the selling securityholders may sell all or some of their shares under this prospectus from time to time, or in another permitted manner, we cannot assure you as to the actual number of shares that will be sold by the selling securityholders or that will be held by the selling securityholders after completion of any sales. We do not know how long the selling securityholders will hold the shares before selling them. Information concerning the selling securityholders may change from time to time and changed information will be presented in a supplement to this prospectus if and when necessary and required. Beneficial ownership is determined in accordance with Rule 13d-3(d) promulgated by the SEC under the Securities Exchange Act of 1934, as amended.

<b>Name</b>	<b>Number of Shares Owned</b>	<b>Number of Shares to be Offered<sup>(1)(2)</sup></b>	<b>Number of Shares Owned After Offering</b>	<b>Percentage of Shares Owned After Offering</b>
John H. Abeles (3)	124,500	85,000	19,500	*
David M. Bartash (4)	110,500	95,000	15,500	*
Mark Carota (5)	132,500	132,500	0	*
Alexander W. Casdin (6)	225,000	25,000	200,000	*
Richard C. Christopher (7)	107,625	102,625	5,000	*
Robert F. Doman (8)	194,375	179,375	15,000	*
Jay M. Haft (9)	139,500	105,000	34,500	*
Richard C. Lufkin (10)	117,100	117,000	100	*
Marvin E. Lesser(11)	15,000	15,000	0	*
Scott L. Lundahl (12)	133,332	133,125	207	*
Stuart L. Marcus (13)	124,407	124,407	0	*
Magnus Moliteus (14)	75,000	75,000	0	*
William F. O Dell (15)	75,843	75,843	0	*
Michael J. Todisco (16)	48,375	48,375	0	*

\* Less than one percent.

(1) Represents shares beneficially owned by the named individual which have been granted under the

1991 Incentive  
Stock Option  
Plan of Deprenyl  
USA, Inc.  
(Deprenyl USA,  
Inc. is the former  
name of DUSA  
Pharmaceuticals,  
Inc.), the DUSA  
Pharmaceuticals,  
Inc. 1994  
Restricted Stock  
Option Plan, the  
DUSA  
Pharmaceuticals,  
Inc. 1996  
Omnibus Plan, as  
amended, the  
DUSA  
Pharmaceuticals,  
Inc. 2006 Equity  
Compensation  
Plan, as amended  
and individual  
stock option  
agreements with  
Richard C.  
Lufkin and Scott  
Lundahl,  
including shares  
that such  
individual has the  
right to acquire  
upon exercise of  
options or  
warrants vesting  
within sixty  
(60) days of  
July 31, 2009,  
but does not  
include shares  
underlying  
options and  
warrants which  
vest more than  
sixty (60) days  
from such date.  
Also includes all  
shares previously  
issued to such  
individuals after

the exercise of  
options or  
warrants granted  
under the listed  
plans and shares  
of common stock

**Table of Contents**

otherwise  
acquired, or  
beneficially  
owned, by such  
named  
individual.

Unless otherwise  
noted, all persons  
referred to above  
have sole voting  
and sole  
investment  
power.

- (2) Does not  
constitute a  
commitment to  
sell any or all of  
the stated number  
of shares of  
common stock.  
The number of  
shares offered  
shall be  
determined from  
time to time by  
each selling  
securityholder at  
their sole  
discretion.
- (3) Dr. Abeles has  
served as a  
director since  
August 1994.  
Beneficial  
ownership  
includes 39,500  
shares of  
common stock  
and 85,000  
shares of  
common stock  
underlying stock  
options granted  
to Dr. Abeles  
which will have  
vested within  
sixty (60) days

after July 31, 2009. The number of shares owned does not include 7,500 shares of common stock granted to Dr. Abeles which will vest more than sixty (60) days after July 31, 2009. Dr. Abeles shares investment and voting power with regard to 34,500 shares of common stock.

- (4) Mr. Bartash has served as a director since November 2001. Beneficial ownership includes 15,500 shares of common stock and 95,000 shares of common stock underlying stock options granted to Mr. Bartash which will have vested within sixty (60) days after July 31, 2009. The number of shares owned does not include 7,500 shares of common stock granted to Mr. Bartash which will vest more than sixty (60) days after July 31, 2009.

- (5) Mr. Carota joined us in October 1999 and was elected as our Vice President, Operations in February 2000. Beneficial ownership includes 2,750 shares of common stock and 129,750 shares of common stock underlying stock options granted to Mr. Carota which will have vested within sixty (60) days after July 31, 2009. The number of shares owned does not include 81,725 shares of common stock underlying stock options and 36,050 shares of common stock granted to Mr. Carota which will vest more than sixty (60) days after July 31, 2009.
- (6) Mr. Casdin has served as a director since January 2009. Beneficial ownership includes 200,000 shares of common stock and 25,000

shares of  
common stock  
underlying stock  
options granted  
to Mr. Casdin  
which will have  
vested within  
sixty (60) days  
after July 31,  
2009.

- (7) Mr. Christopher  
joined us in  
December 2000  
and was  
appointed to the  
position of Vice  
President,  
Finance and  
Chief Financial  
Officer effective  
February 16,  
2005. Before  
that, Mr.  
Christopher  
served as our  
Vice President,  
Financial  
Planning and  
Business  
Analysis and had  
also served as  
our Director,  
Financial  
Analysis.  
Beneficial  
ownership  
includes 8,250  
shares of  
common stock  
and 99,375  
shares of  
common stock  
underlying stock  
options granted  
to Mr.  
Christopher  
which will have  
vested within  
sixty (60) days  
after July 31,

2009. The number of shares owned does not include 104,725 shares of common stock underlying stock options and 47,350 shares of common stock granted to Mr. Christopher which will vest more than sixty (60) days after July 31, 2009.

- (8) Mr. Doman joined us as our President and Chief Operating Officer on January 3, 2005 and was promoted to President and Chief Executive Officer in June 2007. Beneficial ownership includes 19,750 shares of common stock and 174,625 shares of common stock underlying options granted to Mr. Doman which will have vested within sixty (60) days after July 31, 2009. The number of shares owned does not include 251,275 shares of common stock underlying stock



options and  
107,850 shares of  
common stock  
which will vest  
more than sixty  
(60) days after  
July 31, 2009.

- (9) Mr. Haft has  
served as a  
director since  
September 1996.  
He served as  
Chairman of the  
Board since  
December 2008  
Mr. Haft also  
served as  
Chairman of the  
Board from  
June 2003 to  
December 2004.  
Mr. Haft served  
as Lead Director  
from June 2003  
to January 2005.  
From  
January 2005  
until  
December 2008,  
he served as Vice  
Chairman of the  
Board and Lead  
Director.  
Beneficial  
ownership  
includes 34,500  
shares of  
common stock  
and 105,000  
shares of  
common

**Table of Contents**

stock underlying  
stock options  
granted to  
Mr. Haft which  
will have vested  
within sixty (60)  
days after  
July 31, 2009.

The number of  
shares owned  
does not include  
15,000 shares of  
common stock  
granted to  
Mr. Haft which  
will vest more  
than sixty  
(60) days after  
July 31, 2009.

Under  
Rule 13d-3 of the  
Securities and  
Exchange Act of  
1934, as  
amended,  
Mr. Haft  
disclaims, but  
may be deemed  
to be the  
beneficial owner  
of, the 34,500  
shares of  
common stock  
held indirectly by  
Mr. Haft's spouse.

- (10) Mr. Lufkin has  
served as a  
director since  
January 1992.  
Beneficial  
ownership  
includes 12,100  
shares of  
common stock  
and 105,000  
shares of  
common stock  
underlying stock

options granted to Mr. Lufkin which will have vested within sixty (60) days after July 31, 2009. The number of shares owned does not include 7,500 shares of common stock granted to Mr. Lufkin which will vest more than sixty (60) days after July 31, 2009.

(11) Mr. Lesser has served as a director since June 2009. Beneficial ownership includes 15,000 shares of common stock underlying stock options granted to Mr. Lesser which will have vested within sixty (60) days after July 31, 2009.

(12) Mr. Lundahl joined us in May 1998 and was elected as our Vice President, Regulatory Affairs and Intellectual Property in June 2003. Before that, Mr. Lundahl was our Vice

President,  
Technology and  
Device  
Development  
from June 1999  
until June 2003.  
Beneficial  
ownership  
includes 7,957  
shares of  
common stock  
and 125,375  
shares of  
common stock  
underlying stock  
options granted  
to Mr. Lundahl  
which will have  
vested within  
sixty (60) days  
after July 31,  
2009. The  
number of shares  
owned does not  
include 81,725  
shares of  
common stock  
underlying stock  
options and  
36,050 shares of  
common stock  
granted to  
Mr. Lundahl  
which will vest  
more than sixty  
(60) days after  
July 31, 2009.

- (13) Dr. Marcus was  
elected as our  
Vice President,  
Scientific Affairs  
and Chief  
Medical Officer  
in October 1993.  
Beneficial  
ownership  
includes 2,032  
shares of  
common stock  
and 122,375

shares of common stock underlying stock options granted to Dr. Marcus which will have vested within sixty (60) days after July 31, 2009. The number of shares owned does not include 84,600 shares of common stock underlying stock options and 37,550 shares of common stock granted to Dr. Marcus which will vest more than sixty (60) days after July 31, 2009.

- (14) Mr. Moliteus has served as a director since August 2003. Beneficial ownership includes 15,000 shares of common stock and 60,000 shares of common stock underlying stock options granted to Mr. Moliteus which will have vested within sixty (60) days after July 31, 2009. The number of shares owned does not include 7,500 shares of common stock

granted to Mr. Moliteus which will vest more than sixty (60) days after July 31, 2009.

- (15) Mr. O Dell joined us as our Executive Vice President Sales and Marketing on April 4, 2006. Beneficial ownership includes 2,218 shares of common stock and 73,625 shares of common stock underlying stock options granted to Mr. O Dell which will have vested within sixty (60) days after July 31, 2009. This number does not include 114,725 shares of common stock underlying stock options and 47,350 shares of common stock which will vest more than sixty (60) days after July 31, 2009.

- (16) Mr. Todisco has served as Vice President, Controller since September 2006. Beneficial ownership includes 1,706 shares of

common stock  
and 29,500  
shares of  
common stock  
underlying stock  
options granted  
to Mr. Todisco  
which will have  
vested within  
sixty (60) days  
after July 31,  
2009. The  
number of shares  
owned does not  
include 82,725  
shares of  
common stock  
underlying stock  
options and  
47,050 shares of  
common stock  
granted to  
Mr. Todisco  
which will vest  
more than sixty  
(60) days after  
July 31, 2009.

**Table of Contents**

**PLAN OF DISTRIBUTION**

Shares offered hereby may be sold from time to time directly by or on behalf of the selling securityholders in one or more transactions on the Nasdaq Global Market or on any stock exchange on which the common stock may be listed at the time of sale, in privately negotiated transactions, or through a combination of such methods, at market prices prevailing at the time of sale, at prices related to such prevailing market prices, at fixed prices (which may be changed) or at negotiated prices. The selling securityholders may sell shares through one or more agents, brokers or dealers or directly to purchasers. Such brokers or dealers may receive compensation in the form of commissions, discounts or concessions from the selling securityholders and/or purchasers of the shares or both (which compensation as to a particular broker or dealer may be in excess of customary commissions).

In connection with such sales, the selling securityholders and any participating broker or dealer may be deemed to be underwriters within the meaning of the Securities Act, and any commissions they receive and the proceeds of any sale of shares may be deemed to be underwriting discounts and commissions under the Securities Act.

In order to comply with certain state securities laws, if applicable, the shares may be sold in such jurisdictions only through registered or licensed brokers or dealers. In certain states, the shares may not be sold unless the shares have been registered or qualified for sale in such state or an exemption from regulation or qualification is available and is complied with. Sales of shares must also be made by the selling securityholders in compliance with all other applicable state securities laws and regulations.

In addition to any shares sold hereunder, selling securityholders may, at the same time, sell any shares of common stock owned by them in compliance with all of the requirements of Rule 144, regardless of whether such shares are covered by this reoffer prospectus. There can be no assurance that any of the selling securityholders will sell any or all of the shares offered by them hereby.

DUSA will pay all expenses of the registration of the shares. DUSA has notified certain selling securityholders of the need to deliver a copy of this reoffer prospectus in connection with any sale of the shares.

**LEGAL MATTERS**

The validity of the shares being offered hereby has been passed upon for DUSA by Reed Smith LLP. Nanette W. Mantell, Esq., a partner of Reed Smith LLP, serves as DUSA's Secretary, which is an officer position.

**EXPERTS**

The consolidated financial statements, incorporated in this prospectus by reference from DUSA Pharmaceuticals, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2008 have been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their report, which is incorporated herein by reference. Such financial statements have been so incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.

**WHERE YOU CAN FIND MORE INFORMATION**

We have filed with the SEC a registration statement on Form S-8 under the Securities Act with respect to the shares of common stock offered hereby. This prospectus does not contain all of the information set forth in the registration statement and the exhibits thereto. You can find additional information regarding us and the common stock in the registration statement and the exhibits. Statements contained in this prospectus regarding the contents of any contract or any other document to which reference is made are not necessarily complete,



**Table of Contents**

and, in each instance where a copy of such contract or other document has been filed as an exhibit to the registration statement, reference is made to the copy so filed, each such statement being qualified in all respects by such reference.

We are subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the Exchange Act ), and, in accordance therewith, file reports and other information with the SEC. The registration statement, including exhibits, and the reports and other information filed by us can be inspected without charge at the public reference facilities maintained by the SEC at the SEC's public reference room at 100 F Street, N.E., Washington, D.C. 20549. Copies of such material can be obtained from such offices at fees prescribed by the SEC. The public may obtain information on the operation of the Public Reference room by calling the SEC at 1-800-SEC-0330. The SEC maintains a World Wide Web site that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of this site is <http://www.sec.gov>. In addition, you can also access documents we file with the SEC at our website, <http://www.dusapharma.com>, which is not a part of this prospectus and is not incorporated herein by reference.

**INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE**

The following documents, which have been filed by us with the SEC pursuant to the Exchange Act, are incorporated by reference in this prospectus as of their respective dates:

- (a) Our Annual Report on Form 10-K for the year ended December 31, 2008;
- (b) Our Quarterly Report on Form 10-Q for the quarter ended March 31, 2009;
- (c) Our Quarterly Report on Form 10-Q for the quarter ended June 30, 2009;
- (d) All other reports filed pursuant to Section 13 or 15(d) of the Exchange Act since December 31, 2008; and
- (e) The description of DUSA's common stock contained in its registration statement on Form 8-A which was filed on January 3, 1992 and amended on Form 8-A12G filed on October 24, 1997, and in DUSA's Quarterly Report on Form 10-Q which was filed on November 12, 1997.

All documents filed by us pursuant to Section 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date hereof and prior to the termination of the offering, other than information furnished pursuant to Item 2.02 or Item 7.01 of Form 8-K or as otherwise permitted by SEC rules and regulations, shall be deemed to be incorporated by reference into this prospectus and to be a part hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement.

**Table of Contents**

We will provide without charge to any person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request of such person, a copy of each document incorporated by reference in the prospectus (other than exhibits to such documents unless such exhibits are specifically incorporated by reference into this prospectus). We will provide such copies at no cost, upon written or oral request, by writing or telephoning us at: **DUSA Pharmaceuticals, Inc.**

**25 Upton Drive**

**Wilmington, Massachusetts 01887**

**Attention: Mr. Richard Christopher**

**Telephone: (978) 657-7500**

**Attention: Mr. Richard Christopher**

**E-mail to: ChristopherR@DusaPharma.com**

Our World Wide Web site is located at [www.dusapharma.com](http://www.dusapharma.com). Information on the Web site is not incorporated by reference into this prospectus.

**Table of Contents**

**1,313,250 Shares**  
**DUSA**  
**PHARMACEUTICALS, INC.**  
Common Stock

**PROSPECTUS**

August 17, 2009

---

**Table of Contents**

**PART II**  
**INFORMATION REQUIRED TO BE IN THE REGISTRATION STATEMENT**

**ITEM 3. Incorporation of Documents by Reference**

The following documents, which have been filed by us with the SEC pursuant to the Exchange Act, are incorporated by reference in this registration statement as of their respective dates:

- (a) Our Annual Report on Form 10-K for the year ended December 31, 2008;
- (b) Our Quarterly Report on Form 10-Q for the quarter ended March 31, 2009;
- (c) Our Quarterly Report on Form 10-Q for the quarter ended June 30, 2009;
- (d) All other reports filed pursuant to Section 13 or 15(d) of the Exchange Act since December 31, 2008; and
- (e) The description of DUSA's common stock contained in its registration statement on Form 8-A which was filed on January 3, 1992 and amended on Form 8-A12G filed on October 24, 1997, and in DUSA's Quarterly Report on Form 10-Q which was filed on November 12, 1997.

All documents filed by us pursuant to Section 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date hereof and prior to the termination of the offering, other than information furnished pursuant to Item 2.02 or Item 7.01 of Form 8-K or as otherwise permitted by SEC rules and regulations, shall be deemed to be incorporated by reference into this prospectus and to be a part hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement.

**ITEM 4. Description of Securities**

Not applicable.

**ITEM 5. Interests of Named Experts and Counsel**

Not applicable.

**ITEM 6. Indemnification of Directors and Officers**

Article 5 of the Company's Certificate of Incorporation, as amended, and New Jersey Business Corporation Act, N.J.S.A. 14A:2-7 provide as follows:

Any director and officer of the Corporation shall not be personally liable to the Corporation or its shareholders for damages for breach of any duty owed to the Corporation or its shareholders, except that this provision shall not relieve a director or officer from liability for any breach of duty based upon an act or omission (a) in breach of such person's duty of loyalty to the Corporation or its shareholders; (b) not in good faith or involving a knowing violation of law; or (c) resulting in receipt by such person of an improper personal benefit.

**Table of Contents**

The Company's By-laws, as amended, pursuant to the New Jersey Business Corporation Act, N.J.S.A. 14A:3-5, provide as follows:

**ARTICLE IV**  
**INDEMNIFICATION**

**Section 1. Actions by Others.** The Corporation (1) shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation) by reason of the fact that he is or was a director, officer or trustee of the Corporation or of any constituent corporation absorbed by the Corporation in a consolidation or merger and (2) except as otherwise required by Section 3 of this Article, may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation) by reason of the fact that he (a) is or was an employee or agent or the legal representative of a director, officer, trustee, employee or agent of the Corporation or of any absorbed constituent corporation, or (b) is or was serving at the request of the Corporation or of any absorbed constituent corporation as a director, officer, employee, agent of or participant in another corporation, partnership, joint venture, trust or other enterprise, or the legal representative of such a person against expenses, costs, disbursements (including attorneys fees), judgments, fines and amounts actually and reasonably incurred by him in good faith and in connection with such action, suit or proceeding if he acted in a manner he reasonably believed to be in or not opposed to the best interests of the Corporation, and with respect to any criminal action or proceeding, he had no reasonable cause to believe that his conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not meet the applicable standard of conduct.

**Section 2. Actions by or in the Right of the Corporation.** The Corporation shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer, trustee, employee or agent of the Corporation or of any constituent corporation absorbed by the Corporation by consolidation or merger, or the legal representative of any such person, or is or was serving at the request of the Corporation or of any absorbed constituent corporation, as a director, officer, trustee, employee, agent of or participant, or the legal representative of any such person in another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys fees) actually and reasonably incurred by him in connection with the defense or settlement of such action or suit if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Corporation unless and only to the extent that the New Jersey Superior Court or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the New Jersey Superior Court or such other court shall deem proper.

**Section 3. Successful Defense.** To the extent that a person who is or was a director, officer, trustee, employee or agent of the Corporation or of any constituent corporation absorbed by the Corporation by consolidation or merger, or the legal representative of any such person, has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in Section 1 or Section 2 of this Article, or in defense of any claim, issue, or matter therein, he shall be indemnified against expenses (including attorneys fees) actually and reasonably incurred by him in connection therewith.

**Table of Contents**

**Section 4. Specific Authorization.** Any indemnification under Section 1 or Section 2 of this Article (unless ordered by a court) shall be made by the Corporation only as authorized in the specific case upon a determination that indemnification of the director, officer, trustee, employee, agent, or the legal representative thereof, is proper in the circumstances because he has met the applicable standard of conduct set forth in said Sections 1 and 2. Such determination shall be made (1) by the Board of Directors by a majority vote of quorum consisting of directors who were not parties to such action, suit or proceeding, or (2) if such a quorum is not obtainable, a quorum of disinterested directors so directs, by independent legal counsel for a written opinion, (3) by the shareholders.

**Section 5. Advance of Expenses.** Expenses incurred by any person who may have a right of indemnification under this Article in defending civil or criminal action, suit or proceeding may be paid by the Corporation in advance of the final distribution of such action, suit or proceeding as authorized by the board of directors upon receipt of an undertaking by or on behalf of the director, officer, trustee, employee, or the legal representative thereof, to repay such amount unless it shall ultimately be determined that he is entitled to be indemnified by the Corporation pursuant to this Article.

**Section 6. Right of Indemnity not Exclusive.** The indemnification and advancement of expenses provided by this Article shall not exclude any other rights to which those seeking indemnification may be entitled under the certificate of incorporation of the Corporation or any by-law, agreement, vote of shareholders or otherwise; provided that no indemnification shall be made to or on behalf of a Director, officer, trustee, employee, agent, or legal representative if a judgment or other final adjudication adverse to such persons establishes that his acts or omissions (a) were in breach of his duty of loyalty to the corporation or its shareholders, (b) were not in good faith or involved a knowing violation of law or (c) resulted in receipt by such person of an improper personal benefit.

**Section 7. Insurance.** The Corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, trustee, employee or agent of the Corporation or of any constituent corporation absorbed by the Corporation by consolidation or merger of the legal representative of such person or is or was serving at the request of the Corporation or of any absorbed constituent corporation as a director, officer, trustee, employee or agent of or participant in another corporation, partnership, joint venture, trust or other enterprise, or the legal representative of any such person against any liability asserted against him and incurred by him in any such capacity, arising out of his status as such or by reason of his being or having been such, whether or not the Corporation would have the power to indemnify him against such liability under the provisions of this Article, the New Jersey Business Corporation Act, or otherwise.

**Section 8. Invalidity of any Provision of this Article.** The invalidity or unenforceability of any provision of this Article shall not affect the validity or enforceability of the remaining provisions of this Article.

We also maintain directors and officers liability insurance which may, in some instances, reimburse us for judgments against us or our directors or officers.

ITEM 7. Exemption from Registration Claimed.

Not applicable.

**Table of Contents**

ITEM 8. Exhibits

**Exhibit No.      Description of Exhibit**

- 4.1            Common Stock specimen, filed as Exhibit 4(a) to the Registrant's Form 10-K for the fiscal year ended December 31, 2002, and is incorporated herein by reference
- 4.2            Rights Agreement, dated as of September 27, 2002, between the Registrant and American Stock Transfer and Trust Company filed as Exhibit 4.0 to Registrant's Current Report on Form 8-K filed October 11, 2002, and is incorporated herein by reference
- 4.3            Rights Certificate relating to the rights granted to holders of common stock under the Rights Agreement filed as Exhibit 4.0 to Registrant's Current Report on Form 8-K, filed on October 11, 2002, and is incorporated herein by reference
- 5.1            Opinion of Reed Smith LLP
- 23.1          Consent of independent registered public accounting firm
- 23.2          Consent of Reed Smith LLP (included in Exhibit 5.1)
- 24.1          Power of Attorney (contained on Signature Page)

ITEM 9. Undertakings

(a) The undersigned registrant hereby undertakes:

(1) to file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) to include in any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii) to reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the Calculation of Registration Fee table in the effective registration statement;

(iii) to include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement; provided, however, that paragraphs (a)(1)(i), and (a)(1)(ii) above do not apply if the registration statement is on Form S-8 and the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

**Table of Contents**

(2) that, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report pursuant to Section 13 (a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.



**Table of Contents**

**SIGNATURES**

*The Registrant:* Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Wilmington, Commonwealth of Massachusetts, on this 17th day of August, 2009.

DUSA PHARMACEUTICALS, INC.

By: /s/ Robert F. Doman  
 Robert F. Doman  
 President and Chief Executive Officer

**POWER OF ATTORNEY**

Know All Men By These Presents, that each person whose signature appears below constitutes and appoints Robert F. Doman and Richard C. Christopher, and each of them singly, as his/her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for him/her and in his/her name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective amendments) to this registration statement or any related registration statement, including any amendment to this registration statement for the purpose of registering additional shares in accordance with General Instruction E to Form S-8, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection with the above premises, as fully to all intents and purposes as he/she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his/her substitute or substitutes, may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated:

/s/ John H. Abeles, MD	Director	August 17, 2009
John H. Abeles, MD		Date
/s/ David M. Bartash	Director	August 17, 2009
David M. Bartash		Date
/s/ Alexander W. Casdin	Director	August 17, 2009
Alexander W. Casdin		Date
/s/ Richard C. Christopher	Vice President, Finance and Chief Financial Officer (principal financial officer and principal accounting officer)	August 17, 2009
Richard C. Christopher		Date

**Table of Contents**

/s/ Robert F. Doman	Director, President and Chief Executive Officer (principal executive officer)	August 17, 2009
Robert F. Doman		Date
/s/ Jay M. Haft, Esq.	Chairman of the Board of Directors	August 17, 2009
Jay M. Haft, Esq.		Date
/s/ Marvin E. Lesser	Director	August 17, 2009
Marvin E. Lesser		Date
/s/ Richard C. Lufkin	Director	August 17, 2009
Richard C. Lufkin		Date
/s/ Magnus Moliteus	Director	August 17, 2009
Magnus Moliteus		Date

**Table of Contents**

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description of Exhibit</b>
4.1	Common Stock specimen, filed as Exhibit 4(a) to the Registrant's Form 10-K for the fiscal year ended December 31, 2002, and is incorporated herein by reference
4.2	Rights Agreement, dated as of September 27, 2002, between the Registrant and American Stock Transfer and Trust Company filed as Exhibit 4.0 to Registrant's Current Report on Form 8-K filed October 11, 2002, and is incorporated herein by reference
4.3	Rights Certificate relating to the rights granted to holders of common stock under the Rights Agreement filed as Exhibit 4.0 to Registrant's Current Report on Form 8-K, filed on October 11, 2002, and is incorporated herein by reference
5.1	Opinion of Reed Smith LLP
23.1	Consent of independent registered public accounting firm
23.2	Consent of Reed Smith LLP (included in Exhibit 5.1)
24.1	Power of Attorney (contained on Signature Page)

II-8